Incyte Corp
(NAS:INCY)
$
69.91
0.07 (0.1%)
Market Cap: 13.47 Bil
Enterprise Value: 11.73 Bil
PE Ratio: 499.36
PB Ratio: 4.25
GF Score: 89/100 Incyte Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022 / 04:30PM GMT
Release Date Price:
$70.53
(-2.31%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Thanks, everyone, for joining us. This is the fireside chat with Incyte. My name is Vikram Purohit. I'm one of the Biotech Analyst for the Morgan Stanley Research. Let me read a brief disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.
With that, very happy to have with me Herve Hoppenot, CEO; and Christiana Stamoulis, CFO from Incyte, thanks for joining us.
Herve Hoppenot
Incyte Corporation - Chairman, President & CEO
Thank you for having us.
Questions & Answers
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Of course, of course. Herve, Christiana just to start off with, could you provide some opening remarks on the current state of the business and just recap for us what do you think some of the key milestones are that Incyte
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot